EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open access · CC BY-NC 4.0

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study

Patrick Vermersch iD, Sophie Arnould, Ralf Gold, Ludwig Kappos, Robert Fox, Amit Bar-Or, Bruce A C Cree, Soudeh Ansari, Daniela Piani Meier, Goeril Karlsson, Nicolas Rouyrre iD, Gavin Giovannoni iD

European Journal of Neurology · 2026-06 · 33 (6)

DOI: 10.1111/ene.70659 ↗

At a glance

Randomisierte kontrollierte Studie in European Journal of Neurology, published online on 2026-06-08. Written by Patrick Vermersch and 11 co-authors. Institution: Université de Lille, Inserm U1172 LilNCog, FHU Precise, Lille, France. Major MEDLINE topics: Multiple Sclerosis, Chronic Progressive, Benzyl Compounds, Azetidines, Wheelchairs. 31 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Novartis pharma AG basel switzerland.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Delaying time to requiring a wheelchair in people living with MS is an important treatment goal to maintain quality of life and guard against increased healthcare costs. In this post hoc analysis, the effects of siponimod versus placebo on time to sustained Expanded Disability Status Scale (EDSS) ≥ 7.0 over the core part of the Phase 3 EXPAND study were assessed.

Methods

The time to sustained EDSS ≥ 7.0 (time to requiring a wheelchair) was analysed for participants with secondary progressive multiple sclerosis (SPMS). Analyses were based on a While on Treatment (WOT) set that censored participants if entering open‐label treatment. Subgroup analyses were conducted in participants with active versus non‐active SPMS (defined based on pre‐study/baseline criteria), and in participants with baseline EDSS 6.5.

Results

In the overall EXPAND population, siponimod reduced the risk of reaching sustained EDSS ≥ 7.0 (requiring a wheelchair) by 40% (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.41–0.88; p = 0.009) versus placebo; the reduction in risk was 51% (HR, 0.49; 95% CI, 0.29–0.81; p = 0.005) versus placebo in participants with active SPMS and 22% (HR, 0.78; 95% CI, 0.42–1.45; p = 0.437) in non‐active SPMS.

Conclusion

Siponimod reduced the risk of requiring a wheelchair in participants with SPMS versus participants receiving placebo, with a greater effect in those with active disease. Time to requiring a wheelchair is a highly relevant treatment goal and an important indicator of treatment effect in patients with SPMS.

Subjects

MeSH terms (MEDLINE)

Multiple Sclerosis, Chronic ProgressiveBenzyl CompoundsAzetidinesWheelchairsSphingosine 1 Phosphate Receptor ModulatorsHumansDisease ProgressionFemaleMiddle AgedMaleDouble-Blind MethodAdult

Author keywords

Markov modelmulti‐state modelsecondary progressive multiple sclerosissiponimodsustained EDSS ≥ 7.0wheelchair

Substances

siponimodBenzyl CompoundsAzetidinesSphingosine 1 Phosphate Receptor Modulators

Authors and institutions

  • Université de Lille, Inserm U1172 LilNCog, FHU Precise, Lille, France.
  • Sanofi, Zwijnaarde (Gent), Belgium.
  • Department of Neurology, St Josef's Hospital, Ruhr University Bochum, Bochum, Germany.
  • Department of Head, Organs, Movement and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and Uni…
  • Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Neurology, Perelman School of Medicine, Center for Neuroinflammation and Experimental Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID profiles: Patrick Vermersch, Nicolas Rouyrre, Gavin Giovannoni

Funding

  • Novartis pharma AG basel switzerland

Cite

APA

Vermersch, P., Arnould, S., Gold, R., Kappos, L., Fox, R., Bar-Or, A., Cree, B. A. C., Ansari, S., Meier, D. P., Karlsson, G., Rouyrre, N., & Giovannoni, G. (2026). Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. European Journal of Neurology, 33(6). https://doi.org/10.1111/ene.70659

Vancouver

Vermersch P, Arnould S, Gold R, Kappos L, Fox R, Bar-Or A, et al. Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. European Journal of Neurology. 2026;33(6). doi:10.1111/ene.70659

BibTeX
@article{Vermersch2026,
  author = {Vermersch, Patrick and Arnould, Sophie and Gold, Ralf and Kappos, Ludwig and Fox, Robert and Bar-Or, Amit and Cree, Bruce A C and Ansari, Soudeh and Meier, Daniela Piani and Karlsson, Goeril and Rouyrre, Nicolas and Giovannoni, Gavin},
  title = {Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {6},
  doi = {10.1111/ene.70659}
}
Start for free →